Carnegie Investment Counsel Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Carnegie Investment Counsel bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 300,260 shares of the company’s stock, valued at approximately $5,531,000.

Other institutional investors have also recently modified their holdings of the company. Diversify Advisory Services LLC bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $701,000. Sei Investments Co. lifted its position in shares of Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after acquiring an additional 37,890 shares during the period. Quantbot Technologies LP lifted its position in shares of Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after acquiring an additional 208,621 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HIMS has been the subject of several recent analyst reports. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. TD Cowen upped their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Bank of America dropped their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, September 13th. Finally, Jefferies Financial Group upped their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus target price of $19.86.

Hims & Hers Health Trading Up 4.7 %

Shares of HIMS stock opened at $18.69 on Monday. The stock has a market cap of $4.01 billion, a price-to-earnings ratio of 233.65 and a beta of 1.06. The stock has a 50-day moving average of $16.41 and a 200-day moving average of $17.38. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s quarterly revenue was up 51.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at $551,777.94. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the sale, the insider now owns 185,326 shares in the company, valued at $4,077,172. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $16.47, for a total value of $3,110,985.36. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $551,777.94. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 564,305 shares of company stock valued at $9,124,922. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.